Get the Stockscreener App
4.53
5.10%
0.22
After Hours:
4.51
-0.02
-0.44%
Arbutus Biopharma Corp stock is traded at $4.53, with a volume of 2.55M.
It is up +5.10% in the last 24 hours and down -1.52% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$4.31
Open:
$4.4
24h Volume:
2.55M
Relative Volume:
1.18
Market Cap:
$872.03M
Revenue:
$14.08M
Net Income/Loss:
$-33.50M
P/E Ratio:
-25.83
EPS:
-0.1754
Net Cash Flow:
$-39.72M
1W Performance:
+6.59%
1M Performance:
-1.52%
6M Performance:
+4.86%
1Y Performance:
+34.42%
1-Day Range:
$4.385
$4.64
1-Week Range:
$4.14
$4.64
52-Week Range:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.53 | 829.68M | 14.08M | -33.50M | -39.72M | -0.1754 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Arbutus: Q4 Earnings Snapshot - theheraldreview.com
Arbutus Biopharma Hits Day Low of $4.21 Amid Price Pressure - Markets Mojo
Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives - simplywall.st
Arbutus Biopharma 2025 Financials: Reduced Annual Loss, Revenue GrowthNews and Statistics - IndexBox
Arbutus Biopharma Corporation (ABUS) Form 8-K Filing Details, Key Financials, and Company Information - Minichart
Arbutus Biopharma earnings beat by $0.02, revenue topped estimates - Investing.com
Arbutus Biopharma 2025 Annual Report: Clinical Pipeline, Patent Litigation, and Strategic Outlook - Minichart
Arbutus Biopharma Corp expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Arbutus Biopharma (ABUS) Misses EPS Estimates but Exceeds Revenue Expectations - GuruFocus
Arbutus: Fourth Quarter Financial Results Overview - Bitget
Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results - MarketBeat
Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement - Stock Titan
Moderna settlement reshapes Arbutus Biopharma (ABUS) with $950M payout - Stock Titan
Arbutus' imdusiran nets two more HBV functional cures; Q3 2026 capital return eyed after $2.25B deal - Stock Titan
Market Moves: Is Arbutus Biopharma Corporation attractive at current valuation2026 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn
Arbutus Biopharma (ABUS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Moderna to pay about $1 billion to settle Arbutus litigation - MSN
Foursixthree Capital LP Has $8.99 Million Stake in Arbutus Biopharma Corporation $ABUS - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 8.4%Time to Sell? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Moderna Settles Patent Litigation with Arbutus et al. - JD Supra
Arbutus Biopharma Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com
Moderna to Pay About $1 Billion to Settle Arbutus Litigation - Claims Journal
Here's Arbutus Biopharma's share of $950M Moderna settlement - The Business Journals
Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Arbutus Biopharma (ABUS) Reaches Settlement with Moderna Over Pa - GuruFocus
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal By Investing.com - Investing.com Canada
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - Finviz
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com
ABUS: Key Developments and Market Impact - GuruFocus
Moderna's $950 Million Settlement Clears Legal Overhang, Stock SoarsModerna (NASDAQ:MRNA) - Benzinga
Moderna to pay about US$1 bil to settle Arbutus litigation - The Edge Malaysia
Genevant and Arbutus agree $2.25 billion global settlement with Moderna - The Pharma Letter
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Moderna Shares Rise 16% After Company Enters Settlement Agreement With Arbutus Biopharma, Genevant Sciences - Bitget
Moderna To Pay At Least $950M To End COVID-19 Vax IP Fight - Law360
Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement - PharmaLive
Moderna agrees to pay nearly $1B to settle Covid vaccine patent battle - The Business Journals
Arbutus Biopharma (ABUS) and Genevant Reach $2.25 Billion Settle - GuruFocus
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna - TipRanks
Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement - Investing.com
Roivant's Genevant and Arbutus reach $2.25 billion settlement with Moderna - StreetInsider
Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement - Stock Titan
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewswire
Moderna Royalty Loss Raises Covid-Shot Trial Stakes (Correct) - Bloomberg Law News
Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury - TradingView
Key patent ruling boosts Arbutus Biopharma (NASDAQ: ABUS) in Moderna LNP case - Stock Titan
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Intellectia AI
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):